Polyamine metabolism and the hypertrophic heart

Polyamine Cell Signaling: Polyamine Cell Signaling

Volumn , Issue , 2006, Pages 123-137

  Shantz, Lisa M ^a   Giordano, Emanuele ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900097561     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-145-1_7     Document Type: Chapter

References (62)

1. Levy, D., Garrison, R. J., Savage, D. D., Kannel,W. B., and Castelli,W. P. (1990) Prognostic implications of echocardiographically determined left ventricle mass in the Framingham heart study. N. Engl. J. Med. 322, 1561-1566.
2. Sugden, P. H. and Clerk, A. (1998) Cellular mechanisms of cardiac hypertrophy. J. Mol. Med. 76, 725-746.
3. Flamigni, F., Rossoni, C., Stefanelli, C., and Caldarera, C. M. (1986) Polyamine metabolism and function in the heart. J. Mol. Cell. Cardiol. 18, 3-11.
4. Ikeguchi,Y., Wang, X., McCloskey, D. E., et al. (2004) Characterization of transgenic mice with widespread overexpression of spermine synthase. Biochem. J. 381, 701-707.
5. Caldarera, C. M., Casti, A., Rossoni, C., and Visioli, O. (1971) Polyamines and noradrenaline following myocardial hypertrophy. J. Mol. Cell. Cardiol. 3, 121-126.
6. Russell, D. H., Shiverick, K. T., Hamrell, B. B., and Alpert, N. R. (1971) Polyamine synthesis during initial phases of stress-induced cardiac hypertrophy. Am. J. Physiol. 221, 1287-1291.
7. Caldarera, C. M., Orlandini, G., Casti, A., and Moruzzi, G. (1974) Polyamines and nucleic acid metabolism in myocardial hypertrophy of the overloaded heart. J. Mol. Cell. Cardiol. 6, 95-104.
8. Warnica, J. W., Antony, P., Gibson, K., and Harris, P. (1975) The effect of isoprenaline and propranolol on rat myocardial ornithine decarboxylase. Cardiovasc. Res. 9, 793-796.
9. Moruzzi, G., Caldarera, C. M., and Casti, A. (1974) The biological effect of polyamines on heart RNA and histone metabolism. Mol. Cell. Biochem. 3, 153-161.
10. Gibson, K. and Harris, P. (1974) The in vitro and in vivo effects of polyamines on cardiac protein biosynthesis. Cardiovasc. Res. 8, 668-673.
11. Caldarera, C. M., Casti, A., Guarnieri, C., and Moruzzi, G. (1975) Regulation of ribonucleic acid synthesis by polyamines. Biochem. J. 152, 91-98.
12. Ibrahim, J., Schachter, M., Hughes, A. D., and Sever, P. S. (1995) Role of polyamines in hypertension induced by angiotensin II. Cardiovasc. Res. 29, 50-56.
13. Bartolome, J., Huguenard, J., and Slotkin, T. A. (1980) Role of ornithine decarboxylase in cardiac growth and hypertrophy. Science 210, 793-794.
14. Pegg, A. E. (1981) Effect of ?-difluoromethylornithine on cardiac polyamine content and hypertrophy. J. Mol. Cell. Cardiol. 13, 881-887.
15. Cubria, J. C., Reguera, R., Balana-Fouce, R., Ordonez, C., and Ordonez, D. (1998) Polyamine-mediated heart hypertrophy induced by clenbuterol in the mouse. J. Pharm. Pharmacol. 50, 91-96.
16. Tipnis, U. R., He, G. Y., Campbell, G., and Boor, P. J. (2000) Attenuation of isoproterenolmediated myocardial injury in rat by an inhibitor of polyamine synthesis. Cardiovasc. Pathol. 9, 273-80.
17. Thompson, K. E., Friberg, P., and Adams, M. A. (1992) Vasodilators inhibit acute alpha 1-adrenergic receptor-induced trophic responses in the vasculature. Hypertension 20, 809-815.
18. Schluter, K. D., Frischfopf, K., Flesch, M., Rosenkranz, S., Taimor, G., and Piper, H. M. (2000) Central role for ornithine decarboxylase in ?-adrenoceptor mediated hypertrophy. Cardiovasc. Res. 45, 410-417.
19. Steinberg, S. F. (1999) The molecular basis for distinct ?-adrenergic receptor subtype actions in cardiomyocytes. Circ. Res. 85, 1101-1111.
20. Palvimo, J. J., Eisenberg, L. M., and Jänne, O. A. (1991) Protein-DNA interactions in the cAMP responsive promoter region of the murine ornithine decarboxylase gene. Nucleic Acids Res. 19, 3921-3927.
21. Shantz, L. M., Feith, D. J., and Pegg, A. E. (2001) Targeted overexpression of ornithine decarboxylase enhances ?-adrenergic agonist-induced cardiac hypertrophy. Biochem. J. 358, 25-32.
22. Nakano, M., Kanada, T., Matsuzaki, S., et al. (1995) Effect of losartan, an AT1 selective angiotensin II receptor antagonist, on isoproterenol-induced cardiac ornithine decarboxylase activity. Res. Commun. Mol. Pathol. Pharmacol. 88, 21-30.
23. Hunter, J. J. and Chien, K. R. (1999) Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341, 1276-1283.
24. Chu, G., Haghighi, K., and Kranias, E. G. (2002) From mouse to man: understanding heart failure through genetically altered mouse models. J. Card. Failure 8, S432-S449.
25. Janne, J., Alhonen, L., Pietila, M., and Keinanen, T. A. (2004) Genetic approaches to the cellular functions of polyamines in mammals. Eur. J. Biochem. 271, 877-894.
26. Nishimura, K., Nakatsu, F., Kashiwagi, K., Ohno, H., Saito, T., and Igarashi, K. (2002) Essential role of S-adenosylmethionine decarboxylase in mouse embryonic development. Genes Cells 7, 41-47.
27. Pendeville, H., Carpino, N., Marine, J. C., et al. (2001) The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol. Cell. Biol. 21, 6549-6558.
28. Lorenz, B., Francis, F., Gempel, K., et al. (1998) Spermine deficiency in Gy mice caused by deletion of the spermine synthase gene. Hum. Mol. Genet. 7, 541-547.
29. Hillary, R. A., Giordano, E., Pegg, A. E., et al. A lethal phenotype in mice with cardiac overexpression of ornithine decarboxylase. Cardiovasc. Res. In press.
30. Xie, X., Tome, M. E., and Gerner, E. W. (1997) Loss of intracellular putrescine pool-size regulation induces apoptosis. Exp. Cell. Res. 230, 386-392.
31. Tome, M. E., Fiser, S. M., Payne, C. M., and Gerner, E. W. (1997) Excess putrescine inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem. J. 328, 847-854.
32. Schipper, R. G., Penning, L. C., and Verhofstad, A. A. (2000) Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Semin. Cancer Biol. 10, 55-68.
33. Shantz, L. M., Hu, R.-H., and Pegg, A. E. (1996) Regulation of ornithine decarboxylase in a transformed cell line that overexpresses translation initiation factor eIF-4E. Cancer Res. 56, 3265-3269.
34. Tobias, K. E. and Kahana, C. (1995) Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Cell Growth Differentiation 6, 1279-1285.
35. Stefanelli, C., Stanic, I., Zini, M., et al. (2000) Polyamines directly induce release of cytochromec from heart mitochondria. Biochem. J. 347, 875-880.
36. Phillips, L. R. and Nichols, C. G. (2003) Ligand-induced closure of inward rectifier Kir6.2 channels traps spermine in the pore. J. Gen. Physiol. 122, 795-804.
37. Mackintosh, C. A., Feith, D. J., Shantz, L. M., and Pegg, A. E. (2000) Overexpression of antizyme in the hearts of transgenic mice prevents the isoprenaline-induced increase in cardiac ornithine decarboxylase activity and polyamines, but does not prevent cardiac hypertrophy. Biochem. J. 350, 645-653.
38. Hayashi, S. and Murakami, Y. (1995) Rapid and regulated degradation of ornithine decarboxylase. Biochem. J. 306, 1-10.
39. Wu, G. and Morris, S. M., Jr. (1998) Arginine metabolism: nitric oxide and beyond. Biochem. J. 336, 1-17.
40. Palmer, R. M., Ashton, D. S., and Moncada, S. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333, 664-666.
41. Li, H., Meininger, C. J., Hawker, J. R., Jr., et al. (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am. J. Physiol. Endocrinol. Metab. 280, E75-E82.
42. Ignarro, L. J., Buga, G. M., Wei, L. H., Bauer, P. M., Wu, G., and del Soldato, P. (2001) Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA 98, 4202-4208.
43. Simko, F. and Simko, J. (2000) The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol. Res. 49, 37-46.
44. Hu, J., Mahmoud, M. I., and El-Fakahany, E. E. (1994) Polyamines inhibit nitric oxide synthase in rat cerebellum. Neurosci. Lett. 175, 41-45.
45. Blachier, F., Selamnia, M., Robert, V., M'Rabet-Touil, H., and Duée, P. H. (1995) Metabolism of L-arginine through polyamine and nitric oxide synthase pathways in proliferative or differentiated human colon carcinoma cells. Biochim. Biophys. Acta. 1268, 255-262.
46. Bauer, P. M., Buga, G. M., Fukuto, J. M., Pegg, A. E., and Ignarro, L. J. (2001) Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J. Biol. Chem. 276, 34,458-34,464.
47. Daghigh, F., Fukuto, J. M., and Ash, D. E. (1994) Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: implications for the regulation of nitric oxide biosynthesis by arginase. Biochem. Biophys. Res. Commun. 202, 174-180.
48. Buga, G. M.,Wei, L. H., Bauer, P. M., Fukuto, J. M., and Ignarro, L. J. (1998) NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am. J. Physiol. 275, R1256-R1264.
49. Balligand, J.-L. (1999) Regulation of cardiac ?-adrenergic response by nitric oxide. Cardiovasc. Res. 43, 607-620.
50. Ozaki, M., Kawashima, S., Yamashita, T., et al. (2002) Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ. J. 66, 851-856.
51. Jones, S. P., Greer, J. M., van Haperen, R., Duncker, D. J., de Crom, R., and Lefer, D. J. (2003) Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc. Natl. Acad. Sci. USA 100, 4891-4896.
52. Fan, C. C. and Koenig, H. (1988) The role of polyamines in ?-adrenergic stimulation of calcium influx and membrane transport in rat heart. J. Mol. Cell. Cardiol. 20, 789-799.
53. Merry, P. F., Pavoine, C., Belhassen, L., Pecker, F., and Fischmeister, R. (1993) Nitric oxide regulates Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activity. J. Biol. Chem. 268, 26,286-26,295.
54. Barouch, L. A., Harrison, R. W., Skaf, M. W., et al. (2002) Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416, 337-340.
55. Brunner, F., Andrew, P., Wolkart, G., Zechner, R., and Mayer, B. (2001) Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 104, 3097-3102.
56. Heger, J., Godecke, A., Flogel, U., et al. (2002) Cardiac-specific overexpresseion of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ. Res. 90, 93-99.
57. Shi, O., Morris, S. M., Jr., Zoghbi, H., Porter, C. W., and O'Brien, W. E. (2001) Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol. Cell. Biol. 21, 811-813.
58. Iyer, R. K., Yoo, P. K., Kern, R. M., et al. (2002) Mouse model for human arginase deficiency. Mol. Cell. Biol. 22, 4491-4498.
59. Engelhardt, S., Hein, L., Wiesmann, F., and Lohse, M. J. (1999) Progressive hypertrophy and heart failure in ?1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. USA 96, 7059-7064.
60. Du, X.-J., Gao, X.-M.,Wang, B., Jennings, G. L.,Woodcock, E. A., and Dart, A. M. (2000) Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing ?2-adrenergic receptors in the heart. Cardiovasc. Res. 48, 448-454.
61. Iwase, M., Bishop, S. P., Uechi, M., et al. (1996) Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ. Res. 78, 517-524.
62. Roth, D. M., Bayat, H., Drumm, J. D., et al. (2002) Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105, 1989-1994.